JW Pharmaceutical Reports Successful Phase 3 Clinical Trial Results for Gout Treatment Epaminurad

South Korean firm JW Pharmaceutical announced on August 11, 2026, that its gout treatment candidate, epaminurad, successfully met its primary endpoints in a multinational Phase 3 clinical trial. The study evaluated the drug's ability to lower blood uric acid levels in patients suffering from hyperuricemia and gout. Researchers conducted the trial across 52 medical institutions located in five Asian countries and regions, including South Korea, Taiwan, Thailand, Malaysia, and Singapore. The clinical trial involved a total of 612 participants who were monitored for efficacy and safety. Data from the study indicated that the 6mg dosage of epaminurad demonstrated superior performance in reducing uric acid levels compared to existing standard treatments. Specifically, the drug group showed a significantly higher rate of success in achieving target uric acid levels than the control group. According to the company, the study recorded a 12.0-percentage-point difference in efficacy between the epaminurad group and the control group. This statistical superiority provides a strong foundation for the company's upcoming regulatory filings. The trial results also suggested that the drug maintains a manageable safety profile for patients. Regarding safety, the researchers observed no significant difference in the incidence of adverse events between the two treatment groups. The frequency of serious adverse events and drug-related reactions remained similar across the study population. Furthermore, the company reported that no drug-related deaths occurred during the course of the trial. Epaminurad functions by inhibiting the reabsorption of uric acid in the kidneys while simultaneously promoting its excretion from the body. This dual-action mechanism is designed to help patients manage abnormally elevated uric acid levels more effectively. By addressing the root cause of hyperuricemia, the drug aims to provide a reliable long-term treatment option for those with chronic gout. JW Pharmaceutical has already taken steps to prepare for the next phase of the drug's development. The company previously held two face-to-face meetings with regulators to discuss the New Drug Application process. These meetings were part of the Ministry of Food and Drug Safety's New Drug Approval and Review Innovation Plan, which selected epaminurad as a pilot project. Following the positive trial outcomes, the company plans to submit a formal application for domestic product approval in South Korea next year. This submission will rely on the comprehensive data gathered during the multinational study. If approved, the drug would represent a new therapeutic choice for clinicians managing gout patients in the region. The success of this late-stage trial has drawn attention from the financial sector as well. Shares of JW Pharmaceutical experienced a notable increase following the public announcement of the results in August. Investors and medical professionals alike are now looking toward the upcoming regulatory review process. This development marks a significant milestone for the company's research and development pipeline. By focusing on a multinational approach, the researchers were able to gather diverse data that supports the drug's potential utility across different populations. The company remains committed to advancing the treatment through the final stages of the regulatory pathway. As the next steps unfold, the medical community awaits further details on the potential timeline for market availability. The focus will now shift to the formal review by the Ministry of Food and Drug Safety. Successful approval would provide a new tool for managing a condition that affects many patients across Asia.